

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RUI KANG PHARMACEUTICAL GROUP INVESTMENTS LIMITED

銳康藥業集團投資有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

PROFIT WARNING

This announcement is made by Rui Kang Pharmaceutical Group Investments Limited (“**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 17.10(2) of the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (“**GEM Listing Rules**”) and the Inside Information Provisions (as defined under the GEM Listing Rules).

The board (“**Board**”) of directors (“**Directors**”) of the Company wishes to inform the shareholders of the Company (“**Shareholders**”) and potential investors that the Company is expected to continue to record loss for the six months ended 30 June 2014 for its continuing operations. Such loss was mainly attributable to (i) the loss on the financial asset at fair value through profit or loss of approximately HK\$27 million; (ii) the increasing pressure on the cost of sales, including labour costs and raw materials costs; (iii) the decrease in the selling price for certain products due to fierce competition in the People’s Republic of China, which has resulted in a drop in the gross profit margin; (iv) the increase in administrative and selling expenses; and (v) the loss of approximately HK\$6 million on deemed disposal of investment in a joint venture company as a result of issue of performance shares by such joint venture company to a joint venture partner.

The information contained in this announcement is only based on the preliminary assessment by the Board according to the management accounts of the Group for the period under review which has not been confirmed nor audited by the auditors of the Company. The Group is still in the process of finalizing the unaudited consolidated financial statements of the Company for the six months ended 30 June 2014 (“**Interim Results**”). The actual Interim Results may be different from what is disclosed in this announcement. Shareholders and potential investors of the Company are advised to read the Interim Results announcement carefully. The Interim Results are expected to be announced on or around 11 August 2014.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Rui Kang Pharmaceutical Group Investments Limited
LEUNG Pak Hou Anson
Executive Director

Hong Kong, 28 July 2014

As at the date of this announcement, the executive Directors are Mr. CHEUNG Hung (Chairman), Mr. LEUNG Pak Hou Anson and Ms. CHEN Miaoping (Chief Executive Officer); and the independent non-executive Directors are Mr. YEUNG Chi Tit, Mr. YUEN Chun Fai and Mr. LEUNG Ka Fai.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the GEM website at www.hkgem.com for at least 7 days from the date of its publication and on the website of the Company at www.ruikang.com.hk.